7/10/12
Ablexis Announces Licensing of the AlivaMab Mouse Technology to Another Major Pharmaceutical Company

6/15/11
Ablexis Appoints Jake Bauer as Senior Director, Corporate Development and Business Operations

11/18/10
Ablexis Appoints Sean Stevens, Ph.D., as Vice President, Research

10/26/10
Ablexis Forms Five-Member Pharmaceutical Consortium to Fund Technology Development

06/23/10
Xconomy San Francisco: "Ablexis Maps Out New Antibody Drug Strategy with $12M from Third Rock, Pfizer"

06/22/10
Ablexis Appoints R. Scott Greer Chairman of the Board and Richard Hoffman Chief Business Officer

06/02/10
Ablexis Secures $12 Million in Series A Funding to Engineer and Commercialize a Next-Generation Platform for Antibody Drug Discovery

Media Contact:
Dan Budwick
dan@purecommunicationsinc.com
(973) 271-6085